10x Genomics Analyst Price Targets - Benzinga

10x Genomics Inc

TXGNASDAQ

Trade with Public

Trade with Public

$68.59

2.213.33%

At close: Sep 11, 5:00 PM EST

$69.14

0.550.8%

After Hours: Sep 11, 7:54 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

10x Genomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for 10x Genomics (TXG).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

6Buy

10Hold

1Sell

Consensus RatingNeutral# Analysts17Avg. Consensus PT$38Upside to Avg. PT-45.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Neutral	$20→$68
Sep 1, 2026	RBC Capital	Dan Leonard	Initiate	Sector Perform	$70
Aug 12, 2026	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$50→$65
Aug 10, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$42→$47
Aug 10, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$50→$60
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Neutral	$45→$50
Aug 7, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$37→$40
Jul 17, 2026	Leerink Partners	Mike Kratky	PT Raise	Market Perform	$23→$40
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$32→$50
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$22→$37
Jul 8, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$24→$45
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Neutral	$20→$42
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$30→$40
May 12, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$20→$22
May 12, 2026	JP Morgan	Casey Woodring	PT Raise	Neutral	$17→$20
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$22→$32
Apr 20, 2026	B of A Securities	Derik De Bruin	PT Raise	Neutral	$21→$30
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$22→$30
Apr 7, 2026	Citigroup	Patrick Donnelly	PT Raise	Neutral	$18→$24
Mar 31, 2026	William Blair	Matt Larew	Upgrade	Market Perform→Outperform	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.

Benzinga Newsdesk

PRO
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70

RBC Capital analyst Dan Leonard initiates coverage on 10x Genomics (NASDAQ:TXG) with a Sector Perform rating and announces Price Target of $70.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65

Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $42 to $47.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $60.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50

Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.

Benzinga Newsdesk